A secondary RET mutation in the activation loop conferring resistance to vandetanib
Resistance to vandetanib, a type I RET kinase inhibitor, developed in a patient with metastatic lung adenocarcinoma harboring a CCDC6-RET fusion that initially exhibited a response to treatment. The resistant tumor acquired a secondary mutation resulting in a serine-to-phenylalanine substitution at...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5809600/ https://www.ncbi.nlm.nih.gov/pubmed/29434222 http://dx.doi.org/10.1038/s41467-018-02994-7 |
_version_ | 1783299594782769152 |
---|---|
author | Nakaoku, Takashi Kohno, Takashi Araki, Mitsugu Niho, Seiji Chauhan, Rakhee Knowles, Phillip P. Tsuchihara, Katsuya Matsumoto, Shingo Shimada, Yoko Mimaki, Sachiyo Ishii, Genichiro Ichikawa, Hitoshi Nagatoishi, Satoru Tsumoto, Kouhei Okuno, Yasushi Yoh, Kiyotaka McDonald, Neil Q. Goto, Koichi |
author_facet | Nakaoku, Takashi Kohno, Takashi Araki, Mitsugu Niho, Seiji Chauhan, Rakhee Knowles, Phillip P. Tsuchihara, Katsuya Matsumoto, Shingo Shimada, Yoko Mimaki, Sachiyo Ishii, Genichiro Ichikawa, Hitoshi Nagatoishi, Satoru Tsumoto, Kouhei Okuno, Yasushi Yoh, Kiyotaka McDonald, Neil Q. Goto, Koichi |
author_sort | Nakaoku, Takashi |
collection | PubMed |
description | Resistance to vandetanib, a type I RET kinase inhibitor, developed in a patient with metastatic lung adenocarcinoma harboring a CCDC6-RET fusion that initially exhibited a response to treatment. The resistant tumor acquired a secondary mutation resulting in a serine-to-phenylalanine substitution at codon 904 in the activation loop of the RET kinase domain. The S904F mutation confers resistance to vandetanib by increasing the ATP affinity and autophosphorylation activity of RET kinase. A reduced interaction with the drug is also observed in vitro for the S904F mutant by thermal shift assay. A crystal structure of the S904F mutant reveals a small hydrophobic core around F904 likely to enhance basal kinase activity by stabilizing an active conformer. Our findings indicate that missense mutations in the activation loop of the kinase domain are able to increase kinase activity and confer drug resistance through allosteric effects. |
format | Online Article Text |
id | pubmed-5809600 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-58096002018-02-14 A secondary RET mutation in the activation loop conferring resistance to vandetanib Nakaoku, Takashi Kohno, Takashi Araki, Mitsugu Niho, Seiji Chauhan, Rakhee Knowles, Phillip P. Tsuchihara, Katsuya Matsumoto, Shingo Shimada, Yoko Mimaki, Sachiyo Ishii, Genichiro Ichikawa, Hitoshi Nagatoishi, Satoru Tsumoto, Kouhei Okuno, Yasushi Yoh, Kiyotaka McDonald, Neil Q. Goto, Koichi Nat Commun Article Resistance to vandetanib, a type I RET kinase inhibitor, developed in a patient with metastatic lung adenocarcinoma harboring a CCDC6-RET fusion that initially exhibited a response to treatment. The resistant tumor acquired a secondary mutation resulting in a serine-to-phenylalanine substitution at codon 904 in the activation loop of the RET kinase domain. The S904F mutation confers resistance to vandetanib by increasing the ATP affinity and autophosphorylation activity of RET kinase. A reduced interaction with the drug is also observed in vitro for the S904F mutant by thermal shift assay. A crystal structure of the S904F mutant reveals a small hydrophobic core around F904 likely to enhance basal kinase activity by stabilizing an active conformer. Our findings indicate that missense mutations in the activation loop of the kinase domain are able to increase kinase activity and confer drug resistance through allosteric effects. Nature Publishing Group UK 2018-02-12 /pmc/articles/PMC5809600/ /pubmed/29434222 http://dx.doi.org/10.1038/s41467-018-02994-7 Text en © The Author(s) 2018 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Nakaoku, Takashi Kohno, Takashi Araki, Mitsugu Niho, Seiji Chauhan, Rakhee Knowles, Phillip P. Tsuchihara, Katsuya Matsumoto, Shingo Shimada, Yoko Mimaki, Sachiyo Ishii, Genichiro Ichikawa, Hitoshi Nagatoishi, Satoru Tsumoto, Kouhei Okuno, Yasushi Yoh, Kiyotaka McDonald, Neil Q. Goto, Koichi A secondary RET mutation in the activation loop conferring resistance to vandetanib |
title | A secondary RET mutation in the activation loop conferring resistance to vandetanib |
title_full | A secondary RET mutation in the activation loop conferring resistance to vandetanib |
title_fullStr | A secondary RET mutation in the activation loop conferring resistance to vandetanib |
title_full_unstemmed | A secondary RET mutation in the activation loop conferring resistance to vandetanib |
title_short | A secondary RET mutation in the activation loop conferring resistance to vandetanib |
title_sort | secondary ret mutation in the activation loop conferring resistance to vandetanib |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5809600/ https://www.ncbi.nlm.nih.gov/pubmed/29434222 http://dx.doi.org/10.1038/s41467-018-02994-7 |
work_keys_str_mv | AT nakaokutakashi asecondaryretmutationintheactivationloopconferringresistancetovandetanib AT kohnotakashi asecondaryretmutationintheactivationloopconferringresistancetovandetanib AT arakimitsugu asecondaryretmutationintheactivationloopconferringresistancetovandetanib AT nihoseiji asecondaryretmutationintheactivationloopconferringresistancetovandetanib AT chauhanrakhee asecondaryretmutationintheactivationloopconferringresistancetovandetanib AT knowlesphillipp asecondaryretmutationintheactivationloopconferringresistancetovandetanib AT tsuchiharakatsuya asecondaryretmutationintheactivationloopconferringresistancetovandetanib AT matsumotoshingo asecondaryretmutationintheactivationloopconferringresistancetovandetanib AT shimadayoko asecondaryretmutationintheactivationloopconferringresistancetovandetanib AT mimakisachiyo asecondaryretmutationintheactivationloopconferringresistancetovandetanib AT ishiigenichiro asecondaryretmutationintheactivationloopconferringresistancetovandetanib AT ichikawahitoshi asecondaryretmutationintheactivationloopconferringresistancetovandetanib AT nagatoishisatoru asecondaryretmutationintheactivationloopconferringresistancetovandetanib AT tsumotokouhei asecondaryretmutationintheactivationloopconferringresistancetovandetanib AT okunoyasushi asecondaryretmutationintheactivationloopconferringresistancetovandetanib AT yohkiyotaka asecondaryretmutationintheactivationloopconferringresistancetovandetanib AT mcdonaldneilq asecondaryretmutationintheactivationloopconferringresistancetovandetanib AT gotokoichi asecondaryretmutationintheactivationloopconferringresistancetovandetanib AT nakaokutakashi secondaryretmutationintheactivationloopconferringresistancetovandetanib AT kohnotakashi secondaryretmutationintheactivationloopconferringresistancetovandetanib AT arakimitsugu secondaryretmutationintheactivationloopconferringresistancetovandetanib AT nihoseiji secondaryretmutationintheactivationloopconferringresistancetovandetanib AT chauhanrakhee secondaryretmutationintheactivationloopconferringresistancetovandetanib AT knowlesphillipp secondaryretmutationintheactivationloopconferringresistancetovandetanib AT tsuchiharakatsuya secondaryretmutationintheactivationloopconferringresistancetovandetanib AT matsumotoshingo secondaryretmutationintheactivationloopconferringresistancetovandetanib AT shimadayoko secondaryretmutationintheactivationloopconferringresistancetovandetanib AT mimakisachiyo secondaryretmutationintheactivationloopconferringresistancetovandetanib AT ishiigenichiro secondaryretmutationintheactivationloopconferringresistancetovandetanib AT ichikawahitoshi secondaryretmutationintheactivationloopconferringresistancetovandetanib AT nagatoishisatoru secondaryretmutationintheactivationloopconferringresistancetovandetanib AT tsumotokouhei secondaryretmutationintheactivationloopconferringresistancetovandetanib AT okunoyasushi secondaryretmutationintheactivationloopconferringresistancetovandetanib AT yohkiyotaka secondaryretmutationintheactivationloopconferringresistancetovandetanib AT mcdonaldneilq secondaryretmutationintheactivationloopconferringresistancetovandetanib AT gotokoichi secondaryretmutationintheactivationloopconferringresistancetovandetanib |